HELIX BIOPHARMA (HBP:TSE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HELIX BIOPHARMA (HBP:TSE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: trustmanic who wrote (89)	8/11/1997 9:15:00 PM
From: burner	of 193

Levobunolol approved Helix Biopharma Corp HBP Shares issued 13,743,415 Aug 8 close $0.75 Mon 11 Aug 97 News Release Dr Donald Segal reports The company has received a notice of compliance (NOC) and Drug Identification number (DIN) from the Canadian Health Protection Branch for its generic ophthalmic beta-blocker, Levobunolol. Helix previously obtained the Canadian marketing and distribution rights to Levobunolol from Bausch and Lomb Pharmaceuticals, a world leader in the manufacture of ophthalmic pharmaceuticals. The company will now offer the product for sale in Canada under its Rivex Opthalmics label. Levobunolol is used to control intraocular pressure (the rate at which fluid flows into the eye) in patients with chronic open angle glaucoma or mild to moderate ocular hypertension. Glaucoma can cause vision loss and even blindness if left untreated, and the process leading to damaged vision is irreversible. Once glaucoma is diagnosed and treatment begins, most potential vision loss can be prevented. The introduction of Levobunolol completes the company's line of ophthalmic products, all of which will now be aggressively marketed to pharmacists and drug wholesalers across Canada. The company's ophthalmic product line includes a comprehensive range of the most widely prescribed ophthalmic pharmaceuticals available on the market today. The company will continue to pursue its strategy of licencing and registering pharmaceuticals, with the intention of establishing Helix as a major player in the Canadian pharmaceutical industry. (c) Copyright 1997 Canjex Publishing Ltd. canada-stockwatch.com -------------------------------------------------------------------------------------------------- This is approval #1 from HPB; I believe we can expect a couple of others soon as well Dan

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next